Custom Preclinical Angelman Syndrome Research for Early-Stage Drug Development

PsychoGenics is dedicated to supporting your research and advancing your program with tailored preclinical Angelman syndrome studies.   

Angelman syndrome is a neurodevelopmental disorder that emerges early in life, marked by developmental delays, intellectual challenges, and specific behavioral features. 

Ube3a Het Mouse Model

PsychoGenics has experience with a heterozygous Ube3a Het knockout mouse model of Angelman Syndrome, which shows similar genotypic and phenotypic characteristics as the human condition, providing insights crucial for the development of effective treatments.

By closely studying the progression of Angelman syndrome in Ube3a Het mouse neonates, and applying our EEG expertise to measure brainwave patterns, we offer valuable insights that can inform the development of your treatment.

Utilizing EEG in Preclinical Angelman Syndrome Studies

Electroencephalography (EEG) can play an important role in preclinical Angelman syndrome studies, and our team recognizes the immense value of EEG as a powerful tool for assessing sleep/wake patterns and detecting abnormal EEG patterns associated with the disorder.   

Identifying Early Onset Symptoms 

At PsychoGenics, our phenotypic characterization of the Ube3a mouse model of Angelman Syndrome demonstrates a robust deficit in neonatal ultrasonic vocalization and gait impairment in adulthood.

Advancing Your Preclinical Angelman Syndrome Research

Through continued dedication, innovative research methodologies, and collaboration, PsychoGenics strives to propel your research program forward, contributing to meaningful advancements in the Angelman syndrome research community.